Proton Beam Irradiation for Neovascular Age-Related Macular Degeneration
Ophthalmology, ISSN: 0161-6420, Vol: 113, Issue: 11, Page: 2012-2019
2006
- 50Citations
- 29Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations50
- Citation Indexes45
- 45
- CrossRef38
- Policy Citations5
- Policy Citation5
- Captures29
- Readers29
- 29
Article Description
To evaluate safety and visual outcomes after proton therapy for subfoveal neovascular age-related macular degeneration (AMD). Randomized dose-ranging clinical trial. One hundred sixty-six patients with angiographic evidence of classic choroidal neovascularization resulting from AMD and best-corrected visual acuity of 20/320 or better. Patients were assigned randomly (1:1) to receive 16-cobalt gray equivalent (CGE) or 24-CGE proton radiation in 2 equal fractions. Visual acuity was measured using standardized protocol refraction. Complete ophthalmological examinations, color fundus photography, and fluorescein angiography were performed before and 3, 6, 12, 18, and 24 months after treatment. Proportion of eyes losing 3 or more lines of vision from baseline. Kaplan–Meier statistics were used to compare cumulative rates of vision loss between the 2 treatment groups. At 12 months after treatment, 36 eyes (42%) and 27 eyes (35%) lost 3 or more lines of vision in the 16-CGE and 24-CGE groups, respectively. Rates increased to 62% in the 16-CGE group and 53% in the 24-CGE group by 24 months after treatment ( P = 0.40). Radiation complications developed in 15.7% of patients receiving 16 CGE and 14.8% of patients receiving 24 CGE. No significant differences in rates of visual loss were found between the 2 dose groups. Proton radiation may be useful as an adjuvant therapy or as an alternative for patients who decline or are not appropriate for approved therapies.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0161642006007226; http://dx.doi.org/10.1016/j.ophtha.2006.05.036; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33750304884&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/16935343; https://linkinghub.elsevier.com/retrieve/pii/S0161642006007226; https://dx.doi.org/10.1016/j.ophtha.2006.05.036
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know